
German Chancellor Friedrich Merz and Brazilian President Luiz Inácio Lula da Silva met on the sidelines of G20 talks in South Africa on Saturday, after the German leader sparked outrage with comments on the Brazilian city hosting the COP30 climate talks.
Sources close to the chancellor described Saturday's meeting, which focused on the UN Climate Change Conference in Brazil, tropical rainforest protection and the war in Ukraine, as "very harmonious," though it was unclear whether Merz’s controversial comments were discussed.
Merz had travelled to the Amazon city of Belém for a summit two weeks ago ahead of the annual climate conference. On his return to Berlin, the chancellor said he had asked journalists who accompanied him whether any of them wanted to stay.
"No one raised their hand," Merz said. He argued that the reporters were "happy" to return to Germany, which he described as "one of the most beautiful countries in the world."
The statement triggered anger in Brazil, including from President Lula.
At the time, Lula said Merz should have gone to a bar in Belém, danced and tried out the local cuisine.
LATEST POSTS
- 1
Figure out How to Amplify the Resale Worth of Your Kona SUV - 2
Terminal cancer diagnosis announced by JFK's granddaughter - 3
Ancient fire discovery marks significant milestone in human history - 4
Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike - 5
Figure out How to Alter Your Volvo XC40 for Further developed Solace
Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
The Response to Self-improvement: Embracing a Development Outlook
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
‘The White Lotus’ sparked online interest in risky anxiety pills, study says
The Universe of Impeccable Pearls: A Manual for Valuable Gems
‘The White Lotus’ sparked online interest in risky anxiety pills, study says
The Leonid meteor shower is peaking early this week. Here’s what to know
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
5 Advancement Developments in Biotechnology













